What is Brief History of Harrow Company?

How did Harrow transform into a leading ophthalmic company?

In 2023 Harrow completed a transformative $130,000,000 acquisition of five ophthalmic brands from Novartis, accelerating its shift from a 2011 compounding origin to a vertically integrated eye‑care company.

Harrow evolved from Imprimis Pharmaceuticals, born in San Diego to challenge high drug costs, into a national ophthalmic player with FDA‑approved products and broad distribution by 2025.

What is Brief History of Harrow Company?

Explore product strategy and competitive forces via Harrow Porter's Five Forces Analysis.

Harrow was founded on January 11, 2011, originally named Imprimis Pharmaceuticals, Inc., with a mission to reduce costs and improve access to ophthalmic medications through a compounding-led, formulation-first approach.

Founding Story: From Imprimis to Harrow

Mark L. Baum launched the company to address high-priced branded eye drops by using pharmaceutical compounding and customized formulations, beginning with a 'Dropless' cataract surgery prototype.

• Founded on January 11, 2011 as Imprimis Pharmaceuticals, Inc.
• Founder: Mark L. Baum, with legal and finance background and entrepreneurial experience
• Initial MVP: a 'Dropless' cataract formulation targeting post-op non-compliance
• Early growth via private investment, strategic bootstrapping, and acquisition of compounding facilities

The original name Imprimis, Latin for 'among the first,' signaled intent to pioneer personalized, value-based ophthalmic care amid rising demand for affordable alternatives; early traction validated the model and set the Harrow Company history and timeline toward broader product development and market expansion.

Key factual milestones in the Harrow Company timeline: founding date 01/11/2011, initial product validation with the Dropless prototype in the early 2010s, and early scaling through facility acquisitions funded by private capital and revenue reinvestment; these steps form the core of the Harrow Company founding story and its evolution.

For broader context on market positioning and peers, see Competitors Landscape of Harrow

Complete Harrow Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Between 2013 and 2018 Harrow accelerated from a regional compounder to a national provider, fueled by public-market capital and a disruptive pricing model that rapidly expanded its physician and ASC customer base.

NASDAQ IPO and 503B Build-out

In 2013 the company completed a NASDAQ listing, raising capital used to construct multiple 503B outsourcing facilities and scale national distribution.

Product Launches Driving Adoption

Launches of the 'LessDrops' and 'Dropless' ophthalmic lines drove rapid adoption among surgeons, contributing to a nationwide footprint by 2015 serving thousands of physicians and surgery centers.

Disruptive Pricing Strategy

The company often undercut branded rivals by 50% or more, a pricing disruption that accelerated market share gains across ophthalmology and ambulatory surgery centers.

Rebrand and Strategic Pivot

In 2018 the business rebranded as Harrow Health, Inc., creating subsidiaries such as Melt Pharmaceuticals and Surface Ophthalmics to develop proprietary candidates and broaden the platform.

From 2018–2020 the company shifted from compounding toward acquiring and commercializing FDA‑approved assets, responding to tighter compounding regulation and building a specialized sales force via debt and secondary offerings.

Growth Strategy of Harrow

Key milestones in the Harrow Company timeline include the 2013 NASDAQ IPO, nationwide expansion by 2015, the 2018 Harrow Health rebrand, and the post‑2018 pivot to FDA‑approved product commercialization supported by targeted capital raises.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Milestones, Innovations and Challenges trace Harrow Company history through major acquisitions, product launches and regulatory navigation that reshaped its revenue mix and operational model.

Harrow’s innovations include the VEVYE water-free cyclosporine platform and proprietary delivery systems that enabled improved stability and dosing for dry eye therapy. Strategic acquisitions of established ophthalmic brands and the J-coded IHEEZO expanded the company’s branded, high-barrier-to-entry portfolio.

VEVYE: Water-free Cyclosporine

VEVYE introduced a semi-fluorinated alkane vehicle in 2024, delivering cyclosporine with improved ocular tolerability and shelf stability compared with aqueous formulations.

Novartis Portfolio Acquisition

The $130 million 2023 deal added gold-standard anti-inflammatory and anti-infective ophthalmics, immediately increasing recurring revenue and clinical reach.

IHEEZO with J-code

IHEEZO’s unique J-code improved reimbursement access, accelerating hospital and ASC adoption for ocular procedures.

Branded-first Strategy

Pivoting to branded assets reduced exposure to generic price erosion and emphasized products with long-term exclusivity and higher margins.

Manufacturing Integration

By 2025 Harrow had completed complex manufacturing transfers for products like Triesence, meeting quality standards for biologic handling.

Reimbursement Strategy

Targeted coding and contracting efforts, exemplified by IHEEZO’s J-code win, improved payer access and realized measurable uptake in surgical settings.

Key challenges included adapting to the evolving Drug Quality and Security Act framework and FDA scrutiny of 503B operations, which required investment in compliance and facility upgrades. The company also faced generic competition and patent expirations, prompting aggressive IP defense and a strategic shift to branded, high-barrier assets.

DQSA and 503B Compliance

Regulatory changes forced capital investments and process redesigns to satisfy FDA inspection outcomes and maintain outsourcing licenses.

Patent Cliff Pressure

Loss of exclusivity on legacy molecules created revenue risk, driving the company to acquire established branded drugs to stabilize earnings.

Manufacturing Transfers

Taking over production for complex ophthalmics like Triesence required technical training, supply-chain revalidation and capital outlays to ensure uninterrupted supply.

Competitive Generics

Generic entrants pressured pricing on older products, necessitating commercialization shifts and margin protection tactics.

Operational Scaling

Rapid growth from acquisitions required scaling QA, distribution and commercial teams to maintain service levels and regulatory compliance.

Financial Integration

Integrating acquired P&Ls and forecasting synergies demanded tight cash management and clear ROI tracking to justify acquisition multiples.

For context on corporate direction and values see Mission, Vision & Core Values of Harrow.

Harrow Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Timeline and Future Outlook traces Harrow’s strategic evolution from a 2011 startup to a product-driven ophthalmic company positioned to scale in 2026, leveraging key acquisitions, expanded sales coverage, and a portfolio optimization strategy to target multi‑billion dollar markets.

Commercial Ramp of VEVYE

Analysts estimate full commercialization could tap into the $4 billion dry eye market, with projections suggesting potential to double annual revenue by late 2026 if uptake matches forecasts.

Harrow Direct Expansion

Strategic focus on scaling the Harrow Direct distribution platform aims to improve margins and ensure nationwide product availability through a >110 representative field force.

International Licensing

Leadership is exploring licensing and partnership deals to access non‑U.S. markets, targeting incremental revenue streams and broader adoption of core ophthalmic assets.

Portfolio Optimization

Management plans to rationalize and optimize a portfolio of over 50 products, prioritizing high-growth therapies and data‑driven lifecycle management.

For additional strategic context and a marketing perspective on Harrow Company timeline and milestones, see Marketing Strategy of Harrow

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE